

Reference number(s) 3362-A

Initial Prior Authorization Aklief

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Aklief	trifarotene

Indications

FDA-approved Indications

Aklief Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Coverage Criteria

Acne Vulgaris

Authorization may be granted when the requested drug is being prescribed for the topical treatment of acne vulgaris

Aklief PA 3362-A P08-2024_R.docx

© 2024 CVS Caremark. All rights reserved.

Continuation of Therapy

Acne Vulgaris

Authorization may be granted when the requested drug is being prescribed for the topical treatment of acne vulgaris when the following criteria is met:

• The patient has achieved or maintained a positive clinical response as evidenced by improvement (e.g., reduction in number of lesions, patient satisfaction, etc.)

Duration of Approval (DOA)

3362-A: Initial therapy DOA: 4 months; Continuation of therapy DOA: 12 months

References

- 1. Aklief cream [package insert]. Dallas, TX: Galderma Laboratories, LP; October 2023.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed June 19, 2024.
- 3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 06/19/2024).
- 4. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30.